Press coverage about AtriCure (NASDAQ:ATRC) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AtriCure earned a news impact score of 0.17 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 45.9874699522454 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of AtriCure (NASDAQ ATRC) opened at 22.80 on Friday. AtriCure has a 12 month low of $14.36 and a 12 month high of $25.18. The stock’s 50 day moving average is $23.72 and its 200-day moving average is $20.54. The company’s market cap is $782.82 million.
AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 27th. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.05. AtriCure had a negative net margin of 19.56% and a negative return on equity of 19.56%. The firm had revenue of $45.23 million during the quarter, compared to analysts’ expectations of $44.15 million. During the same quarter last year, the company posted ($0.26) earnings per share. The firm’s revenue was up 14.0% compared to the same quarter last year. On average, equities analysts forecast that AtriCure will post ($0.95) EPS for the current year.
A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus reissued a “buy” rating and set a $25.00 price objective on shares of AtriCure in a research report on Sunday, July 30th. BidaskClub downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Needham & Company LLC reissued a “buy” rating and set a $26.00 price objective (up previously from $25.00) on shares of AtriCure in a research report on Friday, July 28th. Zacks Investment Research raised shares of AtriCure from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a research report on Tuesday, May 9th. Finally, Leerink Swann reissued an “outperform” rating and set a $26.00 price objective on shares of AtriCure in a research report on Friday, June 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $25.00.
In related news, Director Elizabeth D. Krell sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $21.44, for a total transaction of $214,400.00. Following the completion of the transaction, the director now owns 24,162 shares of the company’s stock, valued at $518,033.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 10.00% of the company’s stock.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.